345 related articles for article (PubMed ID: 26418580)
21. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
[TBL] [Abstract][Full Text] [Related]
22. Knockout of the Tachykinin Receptor 1 in the Mdr2
Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
[TBL] [Abstract][Full Text] [Related]
23. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
24. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.
Fickert P; Stöger U; Fuchsbichler A; Moustafa T; Marschall HU; Weiglein AH; Tsybrovskyy O; Jaeschke H; Zatloukal K; Denk H; Trauner M
Am J Pathol; 2007 Aug; 171(2):525-36. PubMed ID: 17600122
[TBL] [Abstract][Full Text] [Related]
25. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
26. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
[TBL] [Abstract][Full Text] [Related]
27. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
[TBL] [Abstract][Full Text] [Related]
28. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.
Tabibian JH; O'Hara SP; Trussoni CE; Tietz PS; Splinter PL; Mounajjed T; Hagey LR; LaRusso NF
Hepatology; 2016 Jan; 63(1):185-96. PubMed ID: 26044703
[TBL] [Abstract][Full Text] [Related]
29. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice.
Hasan MN; Chen J; Matye D; Wang H; Luo W; Gu L; Clayton YD; Du Y; Li T
J Lipid Res; 2023 Mar; 64(3):100340. PubMed ID: 36737039
[TBL] [Abstract][Full Text] [Related]
30. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
31. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
Piglionica M; Cariello M; Moschetta A
Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
[TBL] [Abstract][Full Text] [Related]
32. Engineered FGF19
Shi L; Zhao T; Huang L; Pan X; Wu T; Feng X; Chen T; Wu J; Niu J
BMC Biotechnol; 2023 Oct; 23(1):43. PubMed ID: 37789318
[TBL] [Abstract][Full Text] [Related]
33. Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
Li J; Zhu X; Zhang M; Zhang Y; Ye S; Leng Y; Yang T; Kong L; Zhang H
J Hepatol; 2021 Aug; 75(2):400-413. PubMed ID: 33746084
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
[TBL] [Abstract][Full Text] [Related]
35. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.
Johansson H; Svensson JF; Almström M; Van Hul N; Rudling M; Angelin B; Nowak G; Fischler B; Ellis E
J Intern Med; 2020 May; 287(5):534-545. PubMed ID: 31976601
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
Brandl K; Hartmann P; Jih LJ; Pizzo DP; Argemi J; Ventura-Cots M; Coulter S; Liddle C; Ling L; Rossi SJ; DePaoli AM; Loomba R; Mehal WZ; Fouts DE; Lucey MR; Bosques-Padilla F; Mathurin P; Louvet A; Garcia-Tsao G; Verna EC; Abraldes JG; Brown RS; Vargas V; Altamirano J; Caballería J; Shawcross D; Stärkel P; Ho SB; Bataller R; Schnabl B
J Hepatol; 2018 Aug; 69(2):396-405. PubMed ID: 29654817
[TBL] [Abstract][Full Text] [Related]
37. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
38. Roles of FGF19 in liver metabolism.
Kir S; Kliewer SA; Mangelsdorf DJ
Cold Spring Harb Symp Quant Biol; 2011; 76():139-44. PubMed ID: 21813638
[TBL] [Abstract][Full Text] [Related]
39. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.
Taylor AE; Carey AN; Kudira R; Lages CS; Shi T; Lam S; Karns R; Simmons J; Shanmukhappa K; Almanan M; Chougnet CA; Miethke AG
Hepatology; 2018 Nov; 68(5):1905-1921. PubMed ID: 29698570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
